InvestorsHub Logo
Followers 55
Posts 13532
Boards Moderated 0
Alias Born 10/12/2006

Re: MBMoney post# 11187

Friday, 01/27/2017 6:56:21 PM

Friday, January 27, 2017 6:56:21 PM

Post# of 18268
is it officially over?

On January 23, 2017, Health Discovery Corporation (the “Company” or “HDC”) notified NeoGenomics Laboratories, Inc. (“NeoGenomics”) of HDC’s election to terminate all licenses that are subject to the Master License Agreement (the “MLA”) dated January 6, 2012, between the Company and NeoGenomics. The MLA was filed with the Securities and Exchange Commission (“SEC”) on January 11, 2012 as an exhibit to a Current Report on Form 8-K.

The MLA provides for termination of the licenses by HDC upon a material breach by NeoGenomics and HDC is hereby exercising those rights. The Company believes, among other things, that NeoGenomics failed to use best efforts as defined in Section 2.3 of the MLA during the Development Term of the MLA. The termination by HDC does not trigger any early termination penalties for HDC.

Accordingly, NeoGenomics has been directed to cease and desist all uses of the Licensed Products. Additionally, pursuant to the MLA, upon termination, NeoGenomics may not use any product or service based upon the Licensed Technology without infringing upon HDC’s technology.

Furthermore, NeoGenomics has been notified that any patents, issued or pending, owned by either HDC or NeoGenomics which are based in whole or in part on HDC’s patents or technology may not be used by NeoGenomics in the absence of a license authorized by HDC.

Since the Effective Date of the MLA, HDC has worked diligently and was fully supportive to what HDC was led to believe would be a successful commercial launch of Licensed Products by NeoGenomics. NeoGenomics has failed to cure several defaults of their obligations required per the MLA including, but not limited to, reporting related to Licensed Uses along with their corresponding payments. Despite HDC’s numerous prior requests regarding NeoGenomics’ usage of HDC’s technology and NeoGenomics failure to provide the usage reports, HDC has now demanded a full report and compensation for all uses of HDC’s technology as called for in the MLA. HDC will pursue all compensation due from NeoGenomics to the full extent of the law. Additionally, HDC is evaluating potential damages related to the failure of NeoGenomics to perform its obligations per the MLA.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HDVY News